AF
CSTL icon

Allworth Financial’s Castle Biosciences CSTL Stock Holding History

Allworth Financial’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.3K Buy
264
+201
+319% +$4.48K ﹤0.01% 3997
2026
Q1 		$1.55K Buy
63
+33
+110% +$1.08K ﹤0.01% 4432
2025
Q4 		$1.17K Buy
30
+11
+58% +$355 ﹤0.01% 4315
2025
Q3 		$433 Buy
19
+14
+280% +$284 ﹤0.01% 4473
2025
Q2 		$103 Buy
+5
New +$93 ﹤0.01% 4397
2023
Q4 		– Sell
-41
Closed -$693 – 3494
2023
Q3 		$693 Sell
41
-33
-45% -$577 ﹤0.01% 2959
2023
Q2 		$1.02K Sell
74
-57
-44% -$1.16K ﹤0.01% 2729
2023
Q1 		$2.98K Buy
131
+123
+1,538% +$3K ﹤0.01% 2242
2022
Q4 		$188 Hold
8
– – ﹤0.01% 2795
2022
Q3 		$0 Hold
8
– – ﹤0.01% 2735
2022
Q2 		$0 Buy
+8
New +$186 ﹤0.01% 2469

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Allworth Financial's CSTL Position: Q2 2026 in Review

Allworth Financial increased its Castle Biosciences (CSTL) stake by 319% in Q2 2026, buying an estimated $4.48K and bringing the position to 264 shares worth $6.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3997.

Allworth Financial first reported a position in CSTL in Q2 2022 and has held it in 11 quarters since. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Allworth Financial held 264 shares of Castle Biosciences worth $6.3K as of Q2 2026.
  • Allworth Financial bought 201 Castle Biosciences shares in Q2 2026, an estimated $4.48K.
  • Castle Biosciences made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #3997 holding.
  • Allworth Financial first reported a position in Castle Biosciences in Q2 2022 and has held it in 11 quarters since.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.